These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18565884)

  • 1. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo B; Kantoff PW
    J Clin Oncol; 2008 Jun; 26(18):2979-83. PubMed ID: 18565884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
    N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
    Anderson PR; Hanlon AL; Movsas B; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.
    Kamiya N; Suzuki H; Nishimura K; Fujii M; Okegawa T; Matsuda T; Morita T; Takihana Y; Ozono S; Namiki M; Matsubara A; Ichikawa T; Miki T
    Jpn J Clin Oncol; 2014 Mar; 44(3):263-9. PubMed ID: 24516203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.
    Nguyen PL; Chen MH; Beard CJ; Suh WW; Renshaw AA; Loffredo M; McMahon E; Kantoff PW; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1046-52. PubMed ID: 19864082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
    JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
    D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
    JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
    D'Amico AV; Manola J; Loffredo M; Renshaw AA; DellaCroce A; Kantoff PW
    JAMA; 2004 Aug; 292(7):821-7. PubMed ID: 15315996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
    Wo JY; Chen MH; Nguyen PL; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    J Clin Oncol; 2009 Dec; 27(35):6000-5. PubMed ID: 19858385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
    D'Amico AV; Halabi S; Tempany C; Titelbaum D; Philips GK; Loffredo M; McMahon E; Sanford B; Vogelzang NJ; Small EJ;
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):9-15. PubMed ID: 18037582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.